Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines
| Condition | Transformed Migraine, Chronic Daily Headache |
|---|---|
| Phase | Phase 4 |
| Sponsor | Rutgers, The State University of New Jersey |
| Status | Terminated |
| Enrollment | 10 participants |
| Interventions | SPG Block with 5% Lidocaine gel, Amitriptyline |
| Start date | May, 2014 |
| Completion date | Mar 16, 2020 |
| Results posted | Dec 29, 2021 |
Summary
This study will compare a local anesthetic technique that has been used to treat subjects suffering from transformed migraines (chronic migraines) versus medical management with traditional antidepressant Amitriptyline / Elavil. Subjects will be randomized into one of two treatment groups to compare the safety and efficacy of the therapies. Subjects will recieve either sphenopalatine ganglion nerve block with 5% lidocaine gel into the nasopharynx or medical management with traditional antidepressants, Elavil, to produce a reduction in the frequency and severity of the headache. We propose that there will be a difference in the outcomes when comparing the two methods of treating transformed migraines and that one research arm will result in more patient satisfaction and greater efficacy in the treatment of subjects
Number of Daily Headaches
| Amitriptyline / Elavil | 20.5 ± 0.5 Number of Daily Headaches |
|---|---|
| SPG Nerve Block With Lidocaine 5% Gel | 13.4 ± 10.4 Number of Daily Headaches |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner
- Staccato Alprazolam and Photoparoxysmal Response — Nova Pneuma Inc.